Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Imagem de Miniatura
Arquivos
art_PHILLIPS_Mogamulizumab_versus_investigators_choice_of_chemotherapy_regimen_in_2019.PDF (883.5 KB)
Citações na Scopus
50
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FERRATA STORTI FOUNDATION
Autores
PHILLIPS, Adrienne A.
FIELDS, Paul A.
HERMINE, Olivier
RAMOS, Juan C.
BELTRAN, Brady E.
WANDROO, Farooq
FELDMAN, Tatyana
TAYLOR, Graham P.
SAWAS, Ahmed
Citação
HAEMATOLOGICA, v.104, n.5, p.993-1003, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with acute, lymphoma, and chronic subtypes with relapsed/refractory, aggressive disease in the US, Europe, and Latin America. With stratification by subtype, patients were randomized 2: 1 to intravenous mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter (n=47) or investigator's choice of chemotherapy (n=24). The primary end point was confirmed overall response rate (cORR) confirmed on a subsequent assessment at 8 weeks by blinded independent review. ORR was 11% (95% CI: 4-23%) and 0% (95% CI: 0-14%) in the mogamulizumab and chemotherapy arms, respectively. Best response was 28% and 8% in the respective arms. The observed hazard ratio for progression-free survival was 0.71 (95% CI: 0.41-1.21) and, after post hoc adjustment for performance status imbalance, 0.57 (95% CI: 0.337-0.983). The most frequent treatment-related adverse (grade >= 3) events with mogamulizumab were infusion-related reaction and thrombocytopenia (each 9%). Relapsed/refractory ATL is an aggressive, poor prognosis disease with a high unmet need. Investigator's choice chemotherapy did not result in tumor response in this trial; however, mogamulizumab treatment resulted in 11% cORR, with a tolerable safety profile.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/33005
Referências
  1. Amengual JE, 2018, BLOOD, V131, P397, DOI 10.1182/blood-2017-09-806737
  2. Bazarbachi A, 2011, BLOOD, V118, P1736, DOI 10.1182/blood-2011-03-345702
  3. Chihara D, 2014, BRIT J HAEMATOL, V164, P536, DOI 10.1111/bjh.12659
  4. Foss F, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0518-8
  5. Fujiwara H, 2017, BONE MARROW TRANSPL, V52, P484, DOI 10.1038/bmt.2016.313
  6. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  7. HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
  8. Hisada M, 2004, J INFECT DIS, V190, P1605, DOI 10.1086/424598
  9. Hishizawa M, 2010, BLOOD, V116, P1369, DOI 10.1182/blood-2009-10-247510
  10. *IARC WORK GROUP E, 1996, IARC MONOGR EVAL CAR, V67, P1
  11. Ishida T, 2003, CLIN CANCER RES, V9, P3625
  12. Ishida T, 2016, J CLIN ONCOL, V34, P4086, DOI 10.1200/JCO.2016.67.7732
  13. Ishida T, 2015, BRIT J HAEMATOL, V169, P672, DOI 10.1111/bjh.13338
  14. Ishida T, 2012, BLOOD, V120, P1734, DOI 10.1182/blood-2012-03-414490
  15. Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472
  16. Ishii T, 2010, CLIN CANCER RES, V16, P1520, DOI 10.1158/1078-0432.CCR-09-2697
  17. Ishitsuka K, 2015, CANCER SCI, V106, P1219, DOI 10.1111/cas.12735
  18. Iwanaga M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00322
  19. Kim YH, 2018, LANCET ONCOL, V19, P1192, DOI 10.1016/S1470-2045(18)30379-6
  20. O'Connor OA, 2015, J CLIN ONCOL, V33, P2492, DOI 10.1200/JCO.2014.59.2782
  21. O'Connor OA, 2011, J CLIN ONCOL, V29, P1182, DOI 10.1200/JCO.2010.29.9024
  22. O'Connor OA, 2009, J CLIN ONCOL, V27, P4357, DOI 10.1200/JCO.2008.20.8470
  23. Phillips AA, 2010, CANCER-AM CANCER SOC, V116, P3438, DOI 10.1002/cncr.25147
  24. POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
  25. Pro B, 2012, J CLIN ONCOL, V30, P2190, DOI 10.1200/JCO.2011.38.0402
  26. Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
  27. Sekine M, 2017, EUR J HAEMATOL, V98, P501, DOI 10.1111/ejh.12863
  28. Sharma K, 2017, CLIN CANCER RES, V23, P35, DOI 10.1158/1078-0432.CCR-16-1022
  29. SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
  30. Takasaki Y, 2010, BLOOD, V115, P4337, DOI 10.1182/blood-2009-09-242347
  31. Tobinai K, 2003, INT J HEMATOL, V77, P512, DOI 10.1007/BF02986621
  32. TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038/bjc.1994.394
  33. Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200/JCO.2007.11.9958
  34. Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428
  35. UCHIYAMA T, 1977, BLOOD, V50, P481
  36. Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558
  37. Wang M, 2013, LEUKEMIA, V27, P1902, DOI 10.1038/leu.2013.95
  38. YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
  39. Yoshida N, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-014-0321-5
  40. Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03